Patients with stage III non-small-cell lung cancer (nSclc) comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit for patients with pathologic nodal N2 stage III nSclc. we discuss the trial and its implications for future lung cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrclinonc.2009.174 | DOI Listing |
Publication Analysis
Top Keywords
stage iii
8
lung cancer
8
surgery future
4
future directions
4
directions multimodality
4
multimodality therapy
4
therapy nsclc
4
nsclc patients
4
patients stage
4
iii non-small-cell
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!